Dae Hyun Kim1, Ajinkya Pawar2, Joshua J Gagne2, Lily G Bessette2, Hemin Lee2, Robert J Glynn2, Sebastian Schneeweiss2. 1. Brigham and Women's Hospital, Harvard Medical School, Hebrew SeniorLife, and Beth Israel Deaconess Medical Center, Boston, Massachusetts (D.H.K.). 2. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (A.P., J.J.G., L.G.B., H.L., R.J.G., S.S.).
Abstract
BACKGROUND: The role of differing levels of frailty in the choice of oral anticoagulants for older adults with atrial fibrillation (AF) is unclear. OBJECTIVE: To examine the outcomes of direct oral anticoagulants (DOACs) versus warfarin by frailty levels. DESIGN: 1:1 propensity score-matched analysis of Medicare data, 2010 to 2017. SETTING: Community. PATIENTS: Medicare beneficiaries with AF who initiated use of dabigatran, rivaroxaban, apixaban, or warfarin. MEASUREMENTS: Composite end point of death, ischemic stroke, or major bleeding by frailty levels, defined by a claims-based frailty index. RESULTS: In the dabigatran-warfarin cohort (n = 158 730; median follow-up, 72 days), the event rate per 1000 person-years was 63.5 for dabigatran initiators and 65.6 for warfarin initiators (hazard ratio [HR], 0.98 [95% CI, 0.92 to 1.05]; rate difference [RD], -2.2 [CI, -6.5 to 2.1]). For nonfrail, prefrail, and frail persons, HRs were 0.81 (CI, 0.68 to 0.97), 0.98 (CI, 0.90 to 1.08), and 1.09 (CI, 0.96 to 1.23), respectively. In the rivaroxaban-warfarin cohort (n = 275 944; median follow-up, 82 days), the event rate per 1000 person-years was 77.8 for rivaroxaban initiators and 83.7 for warfarin initiators (HR, 0.98 [CI, 0.94 to 1.02]; RD, -5.9 [CI, -9.4 to -2.4]). For nonfrail, prefrail, and frail persons, HRs were 0.88 (CI, 0.77 to 0.99), 1.04 (CI, 0.98 to 1.10), and 0.96 (CI, 0.89 to 1.04), respectively. In the apixaban-warfarin cohort (n = 218 738; median follow-up, 84 days), the event rate per 1000 person-years was 60.1 for apixaban initiators and 92.3 for warfarin initiators (HR, 0.68 [CI, 0.65 to 0.72]; RD, -32.2 [CI, -36.1 to -28.3]). For nonfrail, prefrail, and frail persons, HRs were 0.61 (CI, 0.52 to 0.71), 0.66 (CI, 0.61 to 0.70), and 0.73 (CI, 0.67 to 0.80), respectively. LIMITATIONS: Residual confounding and lack of clinical frailty assessment. CONCLUSION: For older adults with AF, apixaban was associated with lower rates of adverse events across all frailty levels. Dabigatran and rivaroxaban were associated with lower event rates only among nonfrail patients. PRIMARY FUNDING SOURCE: National Institute on Aging.
BACKGROUND: The role of differing levels of frailty in the choice of oral anticoagulants for older adults with atrial fibrillation (AF) is unclear. OBJECTIVE: To examine the outcomes of direct oral anticoagulants (DOACs) versus warfarin by frailty levels. DESIGN: 1:1 propensity score-matched analysis of Medicare data, 2010 to 2017. SETTING: Community. PATIENTS: Medicare beneficiaries with AF who initiated use of dabigatran, rivaroxaban, apixaban, or warfarin. MEASUREMENTS: Composite end point of death, ischemic stroke, or major bleeding by frailty levels, defined by a claims-based frailty index. RESULTS: In the dabigatran-warfarin cohort (n = 158 730; median follow-up, 72 days), the event rate per 1000 person-years was 63.5 for dabigatran initiators and 65.6 for warfarin initiators (hazard ratio [HR], 0.98 [95% CI, 0.92 to 1.05]; rate difference [RD], -2.2 [CI, -6.5 to 2.1]). For nonfrail, prefrail, and frail persons, HRs were 0.81 (CI, 0.68 to 0.97), 0.98 (CI, 0.90 to 1.08), and 1.09 (CI, 0.96 to 1.23), respectively. In the rivaroxaban-warfarin cohort (n = 275 944; median follow-up, 82 days), the event rate per 1000 person-years was 77.8 for rivaroxaban initiators and 83.7 for warfarin initiators (HR, 0.98 [CI, 0.94 to 1.02]; RD, -5.9 [CI, -9.4 to -2.4]). For nonfrail, prefrail, and frail persons, HRs were 0.88 (CI, 0.77 to 0.99), 1.04 (CI, 0.98 to 1.10), and 0.96 (CI, 0.89 to 1.04), respectively. In the apixaban-warfarin cohort (n = 218 738; median follow-up, 84 days), the event rate per 1000 person-years was 60.1 for apixaban initiators and 92.3 for warfarin initiators (HR, 0.68 [CI, 0.65 to 0.72]; RD, -32.2 [CI, -36.1 to -28.3]). For nonfrail, prefrail, and frail persons, HRs were 0.61 (CI, 0.52 to 0.71), 0.66 (CI, 0.61 to 0.70), and 0.73 (CI, 0.67 to 0.80), respectively. LIMITATIONS: Residual confounding and lack of clinical frailty assessment. CONCLUSION: For older adults with AF, apixaban was associated with lower rates of adverse events across all frailty levels. Dabigatran and rivaroxaban were associated with lower event rates only among nonfrail patients. PRIMARY FUNDING SOURCE: National Institute on Aging.
Authors: Neena S Abraham; Peter A Noseworthy; Xiaoxi Yao; Lindsey R Sangaralingham; Nilay D Shah Journal: Gastroenterology Date: 2016-12-30 Impact factor: 22.682
Authors: Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip Journal: Chest Date: 2010-03-18 Impact factor: 9.410
Authors: David J Graham; Marsha E Reichman; Michael Wernecke; Rongmei Zhang; Mary Ross Southworth; Mark Levenson; Ting-Chang Sheu; Katrina Mott; Margie R Goulding; Monika Houstoun; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman Journal: Circulation Date: 2014-10-30 Impact factor: 29.690
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Alan S Go; Daniel E Singer; Sengwee Toh; T Craig Cheetham; Marsha E Reichman; David J Graham; Mary Ross Southworth; Rongmei Zhang; Rima Izem; Margie R Goulding; Monika Houstoun; Katrina Mott; Sue Hee Sung; Joshua J Gagne Journal: Ann Intern Med Date: 2017-11-14 Impact factor: 25.391
Authors: Pedro Silva Cunha; André Viveiros Monteiro; Madalena Coutinho Cruz; Paula Malveiro; João Pedro Reis; Guilherme Portugal; Ana Dias; Rui Cruz Ferreira; Mário Martins Oliveira Journal: Geriatrics (Basel) Date: 2022-02-17
Authors: Chris Wilkinson; Jianhua Wu; Andrew Clegg; Ramesh Nadarajah; Kenneth Rockwood; Oliver Todd; Chris P Gale Journal: Europace Date: 2022-07-21 Impact factor: 5.486
Authors: L P T Joosten; A R de Boer; E J B van Eerde; S van Doorn; A W Hoes; M L Bots; F H Rutten; G J Geersing Journal: Neth Heart J Date: 2022-03-01 Impact factor: 2.854
Authors: Marco Proietti; Marina Camera; Maurizio Gallieni; Luigi Gianturco; Antonio Gidaro; Carlo Piemontese; Giuseppe Pizzetti; Franco Redaelli; Barbara Scimeca; Carlo Sebastiano Tadeo; Matteo Cesari; Giuseppe Bellelli; Laura Adelaide Dalla Vecchia Journal: J Pers Med Date: 2022-03-15